Prognosis of Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Tumor Slope is Prognostic Together with Tumor Burden and Grade Abstract #1452

Introduction: Currently, no prognostic stratification exists in stage IV pNET patients.
Aim(s): To provide prognostic stratification of stage IV pNETs by analyzing 1)prognostic parameters at the time of stage IV diagnosis 2)Per RECIST tumor slope over 3-6 months prior therapy.
Materials and methods: Multicenter retrospective study. Inclusion criteria were: 1)Confirmed pNET naive of therapy 2)Measurable stage IV disease 3)sporadic tumor. Primary endpoint was OS. Two multivariate analyses were performed: model 1 “at the time of stage IV diagnosis”; model 2 "after the characterization of tumor slope".
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Medical Doctor Vincenzo Marotta

To read results and conclusion, please login ...

Further abstracts you may be interested in

#929 Prognostic Role of Smoking in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)
Introduction: Large retrospective series identified several prognostic factors for GEP-NET such as sex, race, age, primary localization, stage or tumor grade. Several studies suggested a prognostic role of smoking in many cancer types. However, no data has been reported in GEP-NET.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Francesc Pons
Authors: Pons F, Mar I, Gallego R, Luque A, ...
#1076 “Wait and Watch” Approach for Small Pancreatic Neuroendocrine Tumors (pNETs): Prognosis and Survival in 51 Consecutive Patients.
Introduction: The most appropriate management for small non-functioning pancreatic neuroendocrine tumors (pNETs) is lacking and whether all these lesions should be routinely resected is still debatable
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Roberta Elisa Rossi
#1133 Prognosis of Stage IV Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) According to the WHO Classification and the Primary Tumor Location
Introduction: WHO classification of GEP-NET is used to predict prognosis, yet survival within each grade shows wide variation. We hypothesized that primary tumor location may be partially responsible of this variability.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: PhD Paula Jiménez-Fonseca
#1376 Pancreatic Neuroendocrine Tumors: Experience of a Tertiary Care Center
Introduction: Pancreatic neuroendocrine tumors (PNET) are rare functionally and biologically heterogeneous tumors accounting for less than 5% of pancreatic cancer
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Rita Assi
#1403 A Univariate Analysis of Factors Influencing Survival in Advanced Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (pNET) are rare and display clinical heterogeneity.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Henning Jann
Keywords: pNET, prognosis